William Blair Investment Management LLC Acquires New Holdings in Halozyme Therapeutics, Inc. $HALO

William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 2,511,050 shares of the biopharmaceutical company’s stock, valued at approximately $196,540,000. William Blair Investment Management LLC owned about 2.21% of Halozyme Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. EP Wealth Advisors LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $686,000. Allworth Financial LP acquired a new stake in Halozyme Therapeutics during the second quarter worth about $2,948,000. Silvant Capital Management LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $56,000. PCM Encore LLC purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $256,000. Finally, Vise Technologies Inc. acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $743,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HALO has been the subject of several research analyst reports. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $83.00 to $110.00 in a report on Friday, August 7th. UBS Group reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Weiss Ratings cut Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $108.17 on Friday. The stock has a market capitalization of $12.28 billion, a price-to-earnings ratio of 32.29, a PEG ratio of 0.43 and a beta of 0.85. The firm’s fifty day simple moving average is $83.19 and its 200-day simple moving average is $73.74. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $108.49.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period last year, the firm posted $1.54 EPS. Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock valued at $5,226,496 in the last ninety days. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.